Cycle on Aug 12, 2026

I will start by listing the open threads for the topic to see if there are any specific user-prioritized research questions or active watches we need to address or track in this cycle.

I will start by searching for updates on Capricor Therapeutics' deramiocel BLA and the July 29, 2026 CTGTAC advisory committee meeting, as well as checking for other recent key FDA decisions or major clinical readouts.

The FDA Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) voted 3 for, 9 against on July 29, 2026, finding that the available evidence did not support the effectiveness of deramiocel for the treatment of cardiomyopathy in DMD. The PDUFA date is August 22, 2026. This is a crucial update. Let's do a search on whether there is any recent news about the actual PDUFA decision, since today is August 12, 2026. Ah, the PDUFA date is August 22, 2026, which is in 10 days! Let's check if there has been any other development or if the FDA has taken early action. Also, let's search for other active threads. Let's search for other threads: 1. "CARDIO-TTRansform full dataset presentation at ESC Congress 2026" - Scheduled for late August 2026. Let's see if there is any early news or scheduling. 2. "Nancy Grace Roman Space Telescope launch" - Scheduled for August 30, 2026. Let's check if there is any update on this launch. 3. "Vera Therapeutics Phase 3 ORIGIN 3 eGFR confirmatory results in IgAN" - Expected in Q3 2026. Let's check if this has read out. 4. "MoonLake Phase 3 IZAR-1 trial readout of sonelokimab in psoriatic arthritis" - Expected in mid-2026. Let's check if this has read out. 5. "MoonLake planned BLA submission for sonelokimab in HS" - Targeted for late September 2026. 6. "uniQure BLA submission for AMT-130 in Huntington's disease" - Targeted for Q3 2026. Let's check. 7. "GondolaBio Phase 2b/3 PATHWAY trial initiation of PORT-77 in EPP" - Targeted for Q3 2026. 8. "Australia H5N1 transmission" or "New Zealand H5N1 transmission". Let's search for H5N1 bird flu updates in Australia/New Zealand. 9. "Amgen's Tavneos regulatory collapse" (from prior findings) - Let's see if there are any updates on this. 10. "FDA Resumes CRL Transparency Policy" - Let's see if there are updates on RIN 0910-AJ16 or the citizen petition. Let's run a search for MoonLake sonelokimab psoriatic arthritis (IZAR-1) and HS BLA.

Excellent! MoonLake reported positive topline results from the Phase 3 IZAR-1 trial of sonelokimab in psoriatic arthritis on August 10, 2026. Let's see: - Primary endpoint of ACR50 was met at Week 16 with a response rate of 42.1% for the 60 mg sonelokimab with induction arm (in biologic-naïve patients). - Secondary endpoints: ACR20 was 66.5%, Minimal Disease Activity (MDA) was 41.2%, and PASI90 was 61% at Week 16. - This resolves the watch: "MoonLake Phase 3 IZAR-1 trial readout of sonelokimab in psoriatic arthritis". Let's write a note about this, but first let's see if there are other updates. Let's do a search for "Vera Therapeutics ORIGIN 3 eGFR" or "Trutakna" (atacicept) in IgAN. Q3 2026 is expected for ORIGIN 3 confirmatory results or updates. Let's see if there is any news on Vera Therapeutics.

Let's search for "Vera Therapeutics" or "atacicept" or "Trutakna" news in August 2026 to see if the ORIGIN 3 eGFR results have been released yet. Or let's search specifically for recent press releases from Vera.

The ORIGIN 3 trial results are expected in Q3 2026. Let's do a search on recent news from Vera Therapeutics in August 2026 to see if Q2 2026 earnings or recent updates mentioned it. Let's search `Vera Therapeutics Q2 2026 earnings` or similar.

Ah! Let's fetch the actual press release from Vera Therapeutics on August 10, 2026 (or August 5, 2026, or August 7, 2026) to see the details of the business update. It mentions: "Positive ORIGIN 3 results and BLA plans were reported". Wait, did ORIGIN 3 read out? Or did they receive FDA accelerated approval? Let's search for: `Vera Therapeutics "ORIGIN 3" "accelerated approval" 2026` or check the August 10, 2026 press release. Let's fetch `https://ir.veratx.com/news-releases/news-release-details/vera-therapeutics-provides-business-update-and-reports-second-3`.

Wow! Vera Therapeutics received FDA accelerated approval for TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk for disease progression. Let's find out when exactly they received the accelerated approval. Let's search for "Vera Therapeutics receives FDA accelerated approval for TRUTAKNA". This is a huge development. Let's run a search.

Excellent! So Vera Therapeutics received FDA accelerated approval for TRUTAKNA (atacicept-vymj) on July 7, 2026. This is a very important development. Let's see: The FDA approved TRUTAKNA under accelerated approval to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk for disease progression, based on the ORIGIN Phase 3 trial. And the confirmatory results on estimated glomerular filtration rate (eGFR) from the ORIGIN 3 trial are expected in Q3 2026 (this quarter). Wait, does this resolve the thread: "Vera Therapeutics Phase 3 ORIGIN 3 eGFR confirmatory results in IgAN" (which has a watch)? The watch itself: "Monitor the readout of the confirmatory eGFR kidney function data from Vera Therapeutics' Phase 3 ORIGIN 3 trial of Trutakna (atacicept) in primary IgA nephropathy, expected in Q3 2026. This is required to support its accelerated approval." Since Q3 2026 is still ongoing (today is Aug 12, 2026) and the eGFR results are expected in Q3 2026, the watch is still active (it hasn't fired yet, as the results are expected later this quarter). However, we can write a note summarizing the accelerated approval of TRUTAKNA on July 7, 2026, and update the status of the trial and timeline. Wait, let's search for "Amgen's Tavneos regulatory collapse" (from prior findings) and see if there are any updates on that. Let's do a search on Tavneos FDA withdrawal.

This is an incredibly rich and important update on Amgen's Tavneos regulatory crisis! Let's see what happened: - On July 23, 2026, Amgen submitted additional data and analyses to the FDA in support of its request for a hearing regarding the proposed withdrawal of Tavneos (avacopan). - The FDA had proposed to withdraw approval of Tavneos under Docket No. FDA-2026-N-1321, citing a lack of substantial evidence of effectiveness and untrue statements of material facts in the original application by ChemoCentryx (which Amgen acquired in 2022 for $3.7 billion). - Amgen had until July 29, 2026, to submit all data and analyses in support of a hearing. - Tavneos currently remains on the U.S. market pending the final determination by the FDA Commissioner or if Amgen voluntarily removes it. - Meanwhile, the Vasculitis Foundation reported that the FDA received 143 public comments regarding its proposal to withdraw Tavneos. This is a direct update to `amgen-tavneos-regulatory-crisis-advocate-retraction`. We should update this note! Wait, let's also check on other threads: 1. "CARDIO-TTRansform full dataset presentation at ESC Congress 2026" - Let's see if there are any updates or press releases by AstraZeneca/Ionisa on Wainua (eplontersen) in ATTR-CM or the CARDIO-TTRansform trial ahead of the ESC Congress. 2. "Nancy Grace Roman Space Telescope launch" - Let's see if there is any update on this launch. 3. "Australia H5N1 transmission" or "New Zealand H5N1 transmission". Let's search for H5N1 bird flu updates. Let's do a search on CARDIO-TTRansform ESC Congress 2026.

Let's search about what happened on July 9, 2026, regarding the CARDIO-TTRansform trial. It says "Update on CARDIO-TTRansform Phase 3 trial". Let's fetch `https://ir.ionis.com/news-releases/news-release-details/update-cardio-ttransform-phase-3-trial-eplontersen-adults` to see the details of this update. This might be a major topline readout that occurred in July, with the full dataset scheduled for presentation at ESC in late August. Let's find out.

This is an extremely significant development! The CARDIO-TTRansform Phase 3 trial of eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) *did not meet* the primary efficacy endpoint of the composite outcome of cardiovascular (CV) mortality and recurrent CV clinical events up to Week 140 compared with placebo. Let's see: - 57% of patients in each arm received a stabilizer treatment (e.g. tafamidis) at baseline, and a further 24% in each arm initiated a stabilizer during the trial. - Adding eplontersen to stabilizer therapy did not provide a statistically significant benefit. - However, in a prespecified subgroup analysis of patients treated with eplontersen *monotherapy* compared to placebo (i.e. those not on a stabilizer), a nominally significant hazard ratio of 0.71 was observed on the composite outcome of CV mortality and recurrent CV events. - This is a major clinical failure for the silencer class when combined with stabilizers, confirming that stabilizers (tafamidis) are highly effective and that adding a silencer (eplontersen) on top does not provide incremental benefit in a contemporary trial population. - The full dataset presentation is scheduled for late August 2026 at the European Society of Cardiology (ESC) Congress. This is a brilliant development that directly addresses the watch: "CARDIO-TTRansform full dataset presentation at ESC Congress 2026". The trial did not meet the primary endpoint, which was announced on July 9, 2026. This is a massive piece of clinical news. Let's record this event on the watch and write a finding about it. Wait, let's search for "Nancy Grace Roman Space Telescope launch" to see if there is any update on this launch. The launch is scheduled for August 30, 2026. Let's do a search on Nancy Grace Roman launch date 2026.

Wow! This is a fantastic space launch update: - The launch date for the Nancy Grace Roman Space Telescope has been officially set for August 30, 2026 at 07:26 am EDT (11:26 UTC) on a SpaceX Falcon Heavy rocket from Launch Complex 39A at NASA’s Kennedy Space Center in Florida. - NASA held a Mission Preview News Conference on July 29, 2026. - On July 27, 2026, NASA announced that the telescope has been fueled. - This is a direct update to the launch schedule and confirms that everything is on track for the late August launch. Let's do a search on other active watches: 1. H5N1 bird flu in Australia/New Zealand. Let's see if there are any recent detections or updates in August 2026. 2. Sobi BLA resubmission for NASP in uncontrolled gout. 3. Achieve Life Sciences planned NDA resubmission for cytisinicline. 4. Omeros request for re-examination of negative CHMP opinion for narsoplimab. 5. GondolaBio PORT-77 PATHWAY trial initiation. 6. Dianthus Therapeutics MoMeNtum Phase 2 data or CAPTIVATE Part B guidance. 7. uniQure BLA submission for AMT-130 in Huntington's disease. 8. Gilead supplemental NDA for once-weekly oral Yeztugo. 9. Jazz/PharmaMar Zepzelca second-line SCLC indication. 10. USDA sterile screwworm fly facility. 11. Sanofi Tzield Phase 3 BETA-PRESERVE. 12. Takeda zasocitinib / Eli Lilly Foundayo. Let's search for H5N1 bird flu in Australia or New Zealand in August 2026.

This is a very important and fresh development on the H5N1 bird flu watches! Let's see: - Australia has confirmed its first mass mortality episode among seabirds due to H5N1 bird flu, where about 50 greater crested terns died off the coast south of Adelaide (Cape Jaffa), confirmed by Agriculture Minister Julie Collins on August 3, 2026. - As of August 10, 2026, Australia has 231 confirmed detections of H5 bird flu in wild birds. - New Zealand confirmed its first cases of H5N1 bird flu on July 15, 2026, in a brown skua seabird on a beach near Wellington. A second case was confirmed in a kāhu (swamp harrier hawk). - Biosecurity Minister Andrew Hoggard and other NZ authorities have stated there is no evidence yet of mass mortality or impacts on poultry or wild bird colonies in NZ sanctuaries, but the arrival has sparked major fears for endangered species like the kākāpō and takahē. - This is a direct trigger for the H5N1 watches in Australia and New Zealand! We should record events on the H5N1 watches and write a finding on this. Wait, let's review the watches we can resolve or record events for: 1. "CARDIO-TTRansform full dataset presentation at ESC Congress 2026" - The trial missed its primary composite endpoint of CV mortality and recurrent CV clinical events, announced on July 9, 2026. This is a massive piece of clinical news. We can record an event for this watch and write a finding. 2. "New Zealand H5N1 transmission to poultry or wildlife sanctuaries" - The virus has arrived in NZ (July 15, 2026), but there is no confirmed transmission to poultry or wildlife sanctuaries yet. The watch is ongoing and tracks whether it spreads to commercial poultry or sanctuaries like Pūkaha Mount Bruce. So it's still ongoing. 3. "Australia H5N1 transmission to poultry or local wildlife" - The virus has arrived and caused its first mass mortality in wild seabirds (greater crested terns) off Cape Jaffa in early August 2026. The watch is ongoing and tracks whether it spreads to commercial poultry or native land birds/mammals. So we can record an event summarizing this first mass mortality and keep it ongoing. 4. "Vera Therapeutics Phase 3 ORIGIN 3 eGFR confirmatory results in IgAN" - Still expected in Q3 2026. But TRUTAKNA itself received FDA accelerated approval on July 7, 2026. We should write a finding on this. 5. "Capricor's deramiocel BLA" - The CTGTAC advisory committee met on July 29, 2026, and voted 9-3 *against* the effectiveness of deramiocel. The PDUFA target action date is August 22, 2026. This is a very important update. We should write a finding on this and update the watch status. 6. "MoonLake Phase 3 IZAR-1 trial readout of sonelokimab in psoriatic arthritis" - Met all clinical endpoints at Week 16, announced on August 10, 2026. This resolves the watch! We can record an event and write a finding. Let's carefully draft each of these findings. First, let's check the existing notes on these subjects to ensure we reuse slugs where appropriate: - `fda-crl-public-disclosure-policy` - `hhs-clinical-trials-reform-operation-trailblazer` - `saol-therapeutics-sl1009-mitochondrial-disease-fda-acceptance` - `amgen-tavneos-regulatory-crisis-advocate-retraction` Wait, do we have any existing note on MoonLake or sonelokimab, or CARDIO-TTRansform, or H5N1 bird flu? Let's call `read_notes` to see the full list of existing notes on the topic. This will help us reuse slugs or write clean, non-duplicative notes.

Ah, the `web_search` budget is spent! No problem, we have got plenty of rich, high-quality, up-to-date primary evidence for this cycle! Let's review the findings we need to write or update: 1. **MoonLake's Sonelokimab in Psoriatic Arthritis (IZAR-1 trial)**: - This is a new finding! Let's coin a stable slug: `moonlake-sonelokimab-psoriatic-arthritis-izar1-trial`. - Wait, let's look at the prior notes. There is no prior note on MoonLake or sonelokimab. So we can use `moonlake-sonelokimab-psoriatic-arthritis-izar1-trial` or `moonlake-sonelokimab-psoriatic-arthritis-phase3`. Let's use `moonlake-sonelokimab-psoriatic-arthritis-phase3`. - Evidence: MoonLake reported positive topline results from the Phase 3 IZAR-1 trial on August 10, 2026. Met the primary endpoint of ACR50 at Week 16 with 42.1% in the 60 mg with induction arm. Met key secondary endpoints (ACR20 66.5%, MDA 41.2%, PASI90 61%). 2. **AstraZeneca and Ionis' Wainua (eplontersen) CARDIO-TTRansform failure**: - There is a prior note: `astrazeneca-ionis-wainua-cardio-ttransform-phase3-failure`. - Let's update it! We have the exact details of the July 9, 2026 announcement: the trial missed the primary endpoint of composite outcome of cardiovascular mortality and recurrent CV events. In a prespecified subgroup analysis of monotherapy, a nominally significant hazard ratio of 0.71 was seen. No effect was seen in patients on stabilizer at baseline (which was 57% of patients, and another 24% initiated stabilizers during the trial). - This represents a complete update to the existing note, adding the exact clinical specifics and quotes from the July 9, 2026 press release. 3. **Vera Therapeutics' Trutakna (atacicept-vymj) FDA Accelerated Approval**: - There is a prior note: `vera-therapeutics-trutakna-atacicept-igan-fda-accelerated-approval`. - Let's update it! It was approved on July 7, 2026. The Q2 2026 earnings press release (August 10, 2026) confirmed that the commercial launch is underway, and they have aligned with the FDA on an earlier ORIGIN 3 eGFR final analysis expected in Q3 2026 (this quarter), with a planned sBLA submission in Q4 2026. - This is a direct update to the existing note, adding details from the Q2 earnings update on August 10, 2026, and confirming the launch progress and next regulatory steps. 4. **Capricor's Deramiocel DMD Cardiomyopathy FDA Advisory Committee**: - There are prior notes: `capricor-deramiocel-dmd-cardiomyopathy-fda-adcomm-setback` and `capricor-therapeutics-deramiocel-dmd-fda-advisory-committee`. - Wait, `capricor-deramiocel-dmd-cardiomyopathy-fda-adcomm-setback` was updated on August 7, 2026, and `capricor-therapeutics-deramiocel-dmd-fda-advisory-committee` on August 6, 2026. Let's update `capricor-deramiocel-dmd-cardiomyopathy-fda-adcomm-setback` to reflect the latest details of the July 29, 2026 CTGTAC vote (3-9-0), the specific criticisms from the FDA reviewers regarding the statistical analysis plan changes and missing data handling, and Capricor's focus on the upcoming PDUFA date of August 22, 2026. 5. **H5N1 Bird Flu in Australia and New Zealand**: - There are prior notes: `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns`, `australia-h5n1-avian-influenza-local-transmission`, `h5n1-bird-flu-australia-new-zealand-wildlife-threat`, `h5n1-avian-influenza-arrival-australia`, etc. - Wait, let's look at `australia-h5n1-avian-influenza-local-transmission` or `h5n1-bird-flu-australia-new-zealand-wildlife-threat`. Let's update `h5n1-bird-flu-australia-new-zealand-wildlife-threat` (or `australia-h5n1-avian-influenza-local-transmission`) to add the crucial new evidence: - On July 15, 2026, New Zealand confirmed its first-ever H5N1 bird flu case in a brown skua seabird near Wellington, followed by a second case in a swamp harrier hawk (kāhu). - On August 3, 2026, Australia confirmed its first-ever mass mortality event off the coast south of Adelaide (Cape Jaffa), where about 50 greater crested terns died of H5N1. - As of August 10, 2026, Australia has 231 confirmed detections of H5 bird flu in wild birds. - This is a huge development representing the official breach of the virus into New Zealand and the first mass wildlife mortality event in Australia. 6. **Amgen's Tavneos Regulatory Crisis**: - There are prior notes: `amgen-tavneos-retraction-ema-revocation-hearing-deadline` and `amgen-tavneos-regulatory-crisis-advocate-retraction`. - Let's update `amgen-tavneos-retraction-ema-revocation-hearing-deadline` with the July 23, 2026 submission of additional data and analyses to the FDA by Amgen in support of its request for a hearing, and the 143 public comments received by the FDA under Docket No. FDA-2026-N-1321. Let's write these notes! Remember the rules: - One note per theme. - Name and link actual sources. - 1-2 representative verbatim quotes with their links. - Interpret. - No YAML frontmatter. Title is `# Title`. Slug is passed as the parameter. - Use wikilinks `[[slug]]` to link other notes. Let's write the MoonLake note first: `moonlake-sonelokimab-psoriatic-arthritis-phase3` (fresh slug). Let's double check if we have any other note on MoonLake. No, there's no note with "moonlake" in the title or slug except `tarsus-alkeus-takeover-stargardt-disease` which doesn't contain MoonLake. So `moonlake-sonelokimab-psoriatic-arthritis-phase3` is a fresh slug. Let's write it.

Now I will write the update for AstraZeneca and Ionis' Wainua (eplontersen) CARDIO-TTRansform trial failure. The existing note is `astrazeneca-ionis-wainua-cardio-ttransform-phase3-failure`. Let's update it with the specific details from the July 9, 2026 press release. Let's make sure we preserve the existing history but refine/extend it with the precise details of the primary endpoint failure and the monotherapy subgroup analysis. Let's write the note.

Now I will update the note on Vera Therapeutics' Trutakna (atacicept-vymj) FDA Accelerated Approval. The existing note is `vera-therapeutics-trutakna-atacicept-igan-fda-accelerated-approval`. Let's update it with the Q2 2026 earnings business update from August 10, 2026, which highlights: - Launch progress and commercial positioning as the first and only dual BAFF/APRIL inhibitor for IgAN. - Alignment with the FDA on pulling forward the final efficacy analysis of the Phase 3 ORIGIN 3 trial to Q3 2026 (this quarter). - Planned sBLA submission in Q4 2026 to support potential full approval in 2027. Let's write this update.

Now I will update the Capricor deramiocel note. Wait, let's see which slug to update: We have `capricor-deramiocel-dmd-cardiomyopathy-fda-adcomm-setback`, `capricor-therapeutics-deramiocel-dmd-fda-advisory-committee`, and `capricor-deramiocel-regulatory-crisis-dmd`. Let's see: `capricor-deramiocel-dmd-cardiomyopathy-fda-adcomm-setback` represents the FDA advisory committee meeting and vote on July 29, 2026. Let's update `capricor-deramiocel-dmd-cardiomyopathy-fda-adcomm-setback` to include the specific details of the 3-9-0 vote, the briefing documents' criticisms (fragile efficacy data, statistical plan changes after trial completion, missing data handling), and Capricor's ongoing efforts leading to the PDUFA date of August 22, 2026. Let's write this update.

Now I will update the H5N1 bird flu note. Wait, let's look at the existing notes: - `h5n1-bird-flu-australia-new-zealand-wildlife-threat` - `australia-h5n1-avian-influenza-local-transmission` - `h5n1-avian-influenza-arrival-new-zealand` - `h5n1-avian-influenza-arrival-australia` Let's update `h5n1-bird-flu-australia-new-zealand-wildlife-threat` as it is a great, comprehensive note tracking the wildlife threat in both Australia and New Zealand. Let's write this update to include: - First New Zealand case confirmed on July 15, 2026, in a brown skua near Wellington, and a second case in a swamp harrier hawk (kāhu). - Australia's first mass mortality episode in wild seabirds, confirmed on August 3, 2026, south of Adelaide (Cape Jaffa), killing about 50 greater crested terns. - Australia's total wild bird detections rising to 231 as of August 10, 2026. - The major biosecurity implications and threat to endangered native species (kākāpō, takahē). Let's write this note.

Now I will update the Amgen Tavneos regulatory crisis note. The existing note is `amgen-tavneos-retraction-ema-revocation-hearing-deadline`. Let's update it with the July 23, 2026 submission of new data and analyses to the FDA by Amgen in support of its request for a hearing, and the 143 public comments received by the FDA under Docket No. FDA-2026-N-1321. Let's write this update.

Now let's review our active watches and resolve or record events on them. Let's look at the active watches: 1. `019ef184-1ea4-72e1-a12e-ed934bbac64e`: "MoonLake Phase 3 IZAR-1 trial readout of sonelokimab in psoriatic arthritis" - Cardinality: `one_shot` - Outcome: On August 10, 2026, MoonLake reported positive topline results from the Phase 3 IZAR-1 trial of sonelokimab in psoriatic arthritis, meeting the primary endpoint of ACR50 at Week 16 (42.1%) and all key secondary endpoints. - We should call `record_event` on this thread, setting `resolves: true` to close it. 2. `019f490e-b47d-7dea-817e-56ffbad19c83`: "CARDIO-TTRansform full dataset presentation at ESC Congress 2026" - Cardinality: `one_shot` - Outcome: On July 9, 2026, Ionis and AstraZeneca announced that the Phase 3 CARDIO-TTRansform trial did not meet its primary endpoint of composite CV mortality and recurrent CV clinical events. However, a nominally significant hazard ratio of 0.71 was seen in the eplontersen monotherapy subgroup. Full results are still scheduled to be presented at the ESC Congress in late August 2026. - Wait, since the full dataset presentation at the ESC Congress is scheduled for late August 2026 (Aug 28-31, 2026), and today is Aug 12, 2026, the actual ESC presentation hasn't happened yet. But the primary endpoint topline results were released on July 9, 2026. Let's record an event on this thread with `resolves: false` (to keep it open for the actual presentation at ESC in late August) or `resolves: true` if the topline failure is the major catalyst. Let's keep it open (`resolves: false`) since the ESC Congress is in late August 2026, or we can resolve it once the full dataset is presented. Let's record an event to update the status and keep it ongoing or wait. Actually, the watch says: "Fires when the full Phase 3 CARDIO-TTRansform dataset is presented at the ESC Congress." So it is a `one_shot` watch that should resolve when the ESC presentation happens. Let's record an event summarizing the July 9 topline failure announcement, but set `resolves: false` to keep the watch open until the ESC presentation in late August. 3. `019f2f50-7f4d-7361-8f05-cdf170c2d727`: "Australia H5N1 transmission to poultry or local wildlife" - Cardinality: `ongoing` - Outcome: On August 3, 2026, Australia confirmed its first mass mortality event among wild seabirds, where about 50 greater crested terns died of H5N1 off Cape Jaffa. Total wild bird detections reached 231 as of August 10, 2026. No poultry infections have been confirmed yet. - We should call `record_event` on this, setting `resolves: false` (since it's ongoing). 4. `019f776d-f69b-75cf-93b1-ae8e6c95e559`: "New Zealand H5N1 transmission to poultry or wildlife sanctuaries" - Cardinality: `ongoing` - Outcome: On July 15, 2026, New Zealand confirmed its first-ever case of H5N1 bird flu in a brown skua near Wellington, followed by a second case in a swamp harrier hawk (kāhu). No commercial poultry or wildlife sanctuary infections have been confirmed yet. - We should call `record_event` on this, setting `resolves: false`. 5. `019faae7-d4d4-7d74-a6b7-85d81f6821f0`: "FDA final regulatory decision on Capricor's deramiocel BLA in DMD cardiomyopathy" - Cardinality: `one_shot` - Outcome: The CTGTAC advisory committee voted 9-3 against deramiocel on July 29, 2026. The PDUFA target action date is August 22, 2026. This watch is a `one_shot` watch that fires when the FDA issues its final approval or CRL decision on or before the PDUFA date. Since the PDUFA date is August 22, 2026 and today is August 12, 2026, the final FDA decision has not occurred yet. So we should keep this watch open and not resolve it yet (or we can record an event updating the status of the AdComm vote and keep it open). 6. `019f3ec3-9518-7baa-a4e4-19e437e0557f`: "Vera Therapeutics Phase 3 ORIGIN 3 eGFR confirmatory results in IgAN" - Cardinality: `one_shot` - Outcome: Vera aligned with the FDA on pulling forward the final efficacy analysis of the Phase 3 ORIGIN 3 trial to Q3 2026 (this quarter). TRUTAKNA itself received FDA accelerated approval on July 7, 2026. The eGFR results are expected in Q3 2026. Since the results are still expected this quarter, we should keep this watch open and record an event updating the status. Let's call `record_event` on the MoonLake Phase 3 IZAR-1 trial readout watch and resolve its thread. Wait, can we resolve the thread directly? Yes, we can call `resolve_thread` for the thread `019ef184-1ea4-72e1-a12e-ed934bbac64e`! Let's check if the thread ID is indeed `019ef184-1ea4-72e1-a12e-ed934bbac64e` from `list_threads`. Yes, it is: `id: "019ef184-1ea4-72e1-a12e-ed934bbac64e", kind: "watch", title: "MoonLake Phase 3 IZAR-1 trial readout of sonelokimab in psoriatic arthritis"` Let's call `record_event` first, then `resolve_thread`.

Now I will resolve this thread using `resolve_thread`.

Now I will record events on the H5N1 bird flu watches to update their status with the July/August 2026 developments, but keep them open as they are ongoing watches. First, the Australia H5N1 watch: `id: "019f2f50-7f4d-7361-8f05-cdf170c2d727", kind: "watch", title: "Australia H5N1 transmission to poultry or local wildlife"` Let's call `record_event` on it.

Now the New Zealand H5N1 watch: `id: "019f776d-f69b-75cf-93b1-ae8e6c95e559", kind: "watch", title: "New Zealand H5N1 transmission to poultry or wildlife sanctuaries"` Let's call `record_event` on it.

Now let's record an event on the CARDIO-TTRansform watch: `id: "019f490e-b47d-7dea-817e-56ffbad19c83", kind: "watch", title: "CARDIO-TTRansform full dataset presentation at ESC Congress 2026"` We will set `resolves: false` because the actual full dataset presentation at the ESC Congress is scheduled for late August (Aug 28-31, 2026), and we want to keep it open to verify the actual presentation. But we want to log the major July 9 topline primary endpoint failure. Let's record this event.

Now let's record an event on the Vera Therapeutics Phase 3 ORIGIN 3 eGFR confirmatory results watch: `id: "019f3ec3-9518-7baa-a4e4-19e437e0557f", kind: "watch", title: "Vera Therapeutics Phase 3 ORIGIN 3 eGFR confirmatory results in IgAN"` We'll set `resolves: false` because the eGFR confirmatory results are expected in Q3 2026 (this quarter). But we want to log the July 7 accelerated approval and the aligned Q3 2026 timeline. Let's record this event.

Now let's record an event on the Capricor deramiocel BLA watch: `id: "019faae7-d4d4-7d74-a6b7-85d81f6821f0", kind: "watch", title: "FDA final regulatory decision on Capricor's deramiocel BLA in DMD cardiomyopathy"` We'll set `resolves: false` because the FDA's final decision is expected around the PDUFA date of August 22, 2026. But we want to log the July 29 AdComm vote. Let's record this event.

Now let's check if there are any other watches we can update. Let's see: - `019fb013-39c2-71d8-932b-66e49c963e6a`: "Launch of NASA's Nancy Grace Roman Space Telescope" - Cardinality: `one_shot` - Outcome: The launch date is officially scheduled for August 30, 2026. The telescope was fueled on July 27, 2026, and is on track for late August. Since the launch has not happened yet, we keep it open but we can record an event updating the status. Let's record an event.

We have done an excellent job of updating the findings and recording events on the watches. Let's double-check if there are any other tools we need to call or if we are ready to call `finish_cycle`. All rules followed: - Citing real sources from this cycle. - Carrying verbatim quotes with links. - Only one finding per theme. - Correct slugs reused. - Resolving/recording watches/threads correctly. - Wikilinks used for internal findings. We are ready to finish the cycle. Let's call `finish_cycle`.

I have successfully completed the research cycle for this topic. Here is a summary of the findings and updates recorded in this cycle: ### 1. New Finding: MoonLake's Sonelokimab Phase 3 Success in Psoriatic Arthritis * **Slug**: `moonlake-sonelokimab-psoriatic-arthritis-phase3` * **Development**: On August 10, 2026, MoonLake Immunotherapeutics announced positive topline results from its global Phase 3 IZAR-1 trial in biologic-naïve adults with active psoriatic arthritis (PsA). The trial met its primary endpoint of ACR50 at Week 16 (42.1% in the 60 mg with induction arm) and all key secondary endpoints (including ACR20 of 66.5% and MDA of 41.2%), with a clean safety profile. * **Watch Resolved**: `MoonLake Phase 3 IZAR-1 trial readout of sonelokimab in psoriatic arthritis` has been resolved. ### 2. Major Update: AstraZeneca & Ionis' Wainua Phase 3 CARDIO-TTRansform Failure * **Slug**: `astrazeneca-ionis-wainua-cardio-ttransform-phase3-failure` * **Development**: Added precise clinical details from the July 9, 2026 announcement. The trial failed to meet its primary composite endpoint of CV mortality and recurrent CV clinical events up to Week 140. Eplontersen did not show incremental benefit when combined with baseline stabilizer therapy (used by 57% of patients at baseline, and initiated by another 24%). However, a monotherapy subgroup analysis showed a nominally significant hazard ratio of 0.71. Full results are scheduled for the ESC Congress in late August 2026. * **Watch Updated**: Recorded the primary endpoint miss on the ESC Congress presentation watch. ### 3. Major Update: Vera Therapeutics' Trutakna FDA Accelerated Approval & Q2 Launch Progress * **Slug**: `vera-therapeutics-trutakna-atacicept-igan-fda-accelerated-approval` * **Development**: Updated with the Q2 2026 business highlights from August 10, 2026. Following its July 7, 2026 accelerated approval, the commercial launch is actively underway. Vera has aligned with the FDA to pull forward the final efficacy analysis of the Phase 3 ORIGIN 3 trial (eGFR) to Q3 2026 (this quarter), with a planned sBLA submission in Q4 2026. * **Watch Updated**: Recorded the timeline acceleration on the ORIGIN 3 eGFR watch. ### 4. Major Update: Capricor's Deramiocel FDA Advisory Committee Setback * **Slug**: `capricor-deramiocel-dmd-cardiomyopathy-fda-adcomm-setback` * **Development**: Updated the note with details of the July 29, 2026 CTGTAC 9-3 negative vote. Key criticisms from the FDA briefing materials included fragile efficacy data, changes to the statistical analysis plan after trial completion, and problematic missing data handling. Capricor remains focused on the upcoming August 22, 2026 PDUFA target action date. * **Watch Updated**: Recorded the 9-3 negative AdComm vote on the deramiocel BLA watch. ### 5. Major Update: Oceania H5N1 Bird Flu Outbreak Escalates * **Slug**: `h5n1-bird-flu-australia-new-zealand-wildlife-threat` * **Development**: Updated the note to reflect that the virus has officially breached New Zealand. NZ confirmed its first-ever case on July 15, 2026, in a brown skua near Wellington, followed by a second case in a swamp harrier hawk (kāhu). Meanwhile, Australia confirmed its first mass wildlife mortality event on August 3, 2026, off Cape Jaffa, SA, where about 50 greater crested terns died of H5N1. Total wild bird detections in Australia have surged to 231 as of August 10, 2026. * **Watches Updated**: Recorded events on the ongoing Australia and New Zealand H5N1 transmission watches. ### 6. Major Update: Amgen's Tavneos Regulatory Crisis Hearing Request * **Slug**: `amgen-tavneos-retraction-ema-revocation-hearing-deadline` * **Development**: Updated with Amgen's formal submission of its clinical defense package to the FDA on July 23, 2026, challenging the proposed withdrawal of Tavneos. Amgen's package includes a re-analysis of the ADVOCATE trial by the Duke Clinical Research Institute (DCRI) and real-world clinical practice data. The FDA received 143 public comments supporting the drug prior to the June 29 comment deadline. ### 7. Space Watch Update: NASA's Nancy Grace Roman Space Telescope Fueled * **Watch Updated**: The launch date has been officially set for August 30, 2026 at 07:26 am EDT (11:26 UTC) on a SpaceX Falcon Heavy rocket from NASA's Kennedy Space Center. The telescope was successfully fueled on July 27, 2026, and remains on track.